MEI Pharma

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

You can watch MEI Pharma and buy or sell other stocks, ETFs, and their options commission-free!

About MEIP

Lite Strategy, Inc. is a pharmaceutical company, which engages in the development of pharmaceutical compounds. Its programs include Voruciclib and ME-344. 

CEO
Justin Jay File
CEOJustin Jay File
Employees
5
Employees5
Headquarters
San Diego, California
HeadquartersSan Diego, California
Founded
2000
Founded2000
Employees
5
Employees5

MEIP Key Statistics

Market cap
141.39M
Market cap141.39M
Price-Earnings ratio
-0.58
Price-Earnings ratio-0.58
Dividend yield
—
Dividend yield—
Average volume
217.22K
Average volume217.22K
High today
—
High today—
Low today
—
Low today—
Open price
—
Open price—
Volume
0.00
Volume0.00
52 Week high
$2.26
52 Week high$2.26
52 Week low
$0.6888
52 Week low$0.6888

Stock Snapshot

With a market cap of 141.39M, MEI Pharma(MEIP) trades at $4.65. The stock has a price-to-earnings ratio of -0.58.

During the trading day, MEI Pharma(MEIP) stock saw an opening price of —, a peak of —, and a bottom of —.

Trading volume for MEI Pharma(MEIP) stock has reached 0, versus its average volume of 217.22K.

The stock's 52-week range extends from a low of $0.69 to a high of $2.26.

The stock's 52-week range extends from a low of $0.69 to a high of $2.26.

People also own

Based on the portfolios of people who own MEIP. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.